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1. Introduction 
Malignant pericardial disease represents a common cause of morbidity and mortality in 
patients with cancer. Malignant tumours of the pericardium may occur as primary or 
secondary tumours. Primary tumours of the pericardium occur rarely, and secondary 
involvement of the pericardium constitutes the majority of the cases of malignant disease of 
the pericardium. In necropsy series, the pericardium is involved in 5 to 40% of patients with 
malignant disease (1-3). Autopsy studies overestimate the clinical problem because they 
mostly include terminally ill patients and also identify microscopic metastases even without 
pericardial effusion. For the majority of patients, a clinical manifestation of neoplastic 
pericarditis is absent or remains unrecognised during their lifetime. In a study comparing 
clinical and pathologic features of pericardial metastases, 60%-70% were clinically non 
significant (4). Clinically, neoplastic pericarditis presents itself as acute pericarditis, 
pericardial effusion, effusive-constrictive pericarditis or cardiac tamponade (5). In their 
retrospective analysis from the years 1979 to 2000, the Mayo Clinic reported a decrease of 
the prevalence of cancer among symptomatic pericardial effusion, mainly due to an increase 
of pericardial effusion due to postoperative procedures or perforations from invasive 
procedures, rather than to a decrease of malignant pericarditis cases (6). A Spanish study 
observing the years 1998-2002 and an Italian study observing the years 1996-2003, report a 
neoplastic etiology among pericardial effusion in 13% and 7.3%, respectively (7,8). The 
relative proportions of neoplastic pericarditis in particular population depends on the 
prevalence of cancer and the prevalence of other causes of effusion in particular 
populations.  
2. Clinical picture 
Clinically, neoplastic pericarditis can be presented as acute pericarditis where at least 2 
criteria of the following 4 should be present: 1. characteristic chest pain; 2. pericardial 
friction rub; 3. suggestive electrocardiographic changes; and 4. new or worsening 
pericardial effusion (9). Neoplastic pericarditis is also manifested as effusive-constrictive 
pericarditis where the diastolic filling is limited by the by restricted inelastic pericardium, 
which is inflamed, scarred, or calcified and thicker than normal. Two other clinical 
pictures are pericardial effusions and cardiac tamponade (4,10). In rare cases, pericardial 
effusion is the initial manifestation of malignancy, and the first review of 29 isolated cases 
of cancer first manifested with pericardial effusion was published by Fraser in 1974 
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(11,12). Reports of cardiac tamponade as an initial presentation of malignancy are even 
much less prevalent, but we report a patient with cardiac tamponade as the first 
manifestation of lung cancer, although the occurrence of malignant cardiac tamponade is 
underestimated due to non-specific signs and symptoms (13,14). Acute dyspnea is the 
most commonly presented symptom in a review of malignant tamponade pooling several 
series with an incidence of 78%. The other reported symptoms were cough (46%), chest 
pain (27%), orthopnea (26%), and weakness (19%). On physical examination the most 
frequently detected findings are sinus tachycardia (50%), jugular venous distention (45%), 
hepatomegaly (36%) and peripheral edema (35%). Classical findings of pericardial 
tamponade such as pulsus paradoxus, pericardial rub and Kussmaul’s sign – occurred in 
only 30%, 12% and 5%, respectively (13-15). Despite the assumption that patient presented 
with tamponade have a worse prognosis than the patient with pericardial effusion 
without tamponade, no data are available to allow the stratification of the prognosis 
based on clinical presentation.  
3. Diagnosis 
The ECG changes were suggestive of pericardial involvement in some patients. There are 
reports of sinus tachycardia which is usual in terminal malignancy, but should also be 
considered as an important sign of cardiac involvement. The presence of low voltage in limb 
leads, non-specific T-wave abnormalities, ST-segment elevation, atrial fibrillation and 
electrical alternans are neither common nor specific findings for malignant pericardial 
effusion (5). The chest x-ray showed non-specific cardiomegaly and indicates at least 200 ml 
of pericardial fluid (16). Pleural effusion is presented in more than half of the patients in 
literature (5). The echocardiogram documented the presence and magnitude of pericardial 
effusion which is detected as an echo-free space between the left ventricular posterior wall 
and the lung. As effusion grows in size, we observed besides the echo-free space the 
swinging of the heart, and abnormal septal motion. Echocardiography differentiates cardiac 
tamponade from other causes of systemic venous hypertension and arterial hypotension, 
including constrictive pericarditis, cardiomyopathy and right ventricular infarction. Typical 
echocardiographic findings in tamponade include late diastolic collapse of the right atrium 
and early diastolic collapse of the right ventricle when the intrapericardial pressure exceeds 
intracavitary pressure. Left atrial collapse, which can occur in tamponade, is very specific 
but is not sensitive for tamponade. Abnormal septal motion is described with bulges of the 
intraventricular septum during inspiration into the left ventricle due to an increased 
systemic venous return to the right ventricle and a limited expansion of the right ventricular 
free wall due to the increase in intrapericardial pressure. With expiration, the transmitral 
pressure gradient increases and the systemic venous return decreases and we observe a 
reversal of diastolic flow in the hepatic veins (17). Echocardiography also guides 
pericardiocentesis (18). Cardiac computed tomography (CT) and cardiac magnetic 
resonance imaging (CMR) are increasingly being used in the diagnosis of pericardial 
diseases. Both imaging modalities are very sensitive in the detection of generalised or 
loculated effusions and can also be used to measure the pericardial thickness (19).  
Pericardial effusions in patients with cancer are not always due to malignancy. Other causes 
of pericardial effusion are radiation-induced, idiopathic, hypoalbuminemic, drug-related or 
uremic (5). Defining the cause of a pericardial effusion in a patient with cancer is of vital 
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importance. The gross appearance of the pericardial fluid is not useful in differentiating 
malignant from non-malignant effusion (20). A cytological examination of pericardial fluid 
confirmed the diagnosis of malignant pericardial effusion in 65% to 85% of cases (21). Even 
with accurate sampling and cytopreparatory techniques, the diagnosis is not always simple, 
and sometimes impossible. In cytology-negative samples of pericardial fluid the dosage of 
tumour markers such as carcinoembryonic antigen (CEA), neuron-specific enolase (NSE), 
serum cytocheratin 19 fragments (CYFRA 21-1) and carbohydrate antigens CA 125, CA 15-3 
and CA 19-9 may be helpful in the setting of an equivocal diagnosis (22). However, there is 
no tumor marker that alone has sufficient diagnostic accuracy in discriminating between 
malignant and benign pericardial diseases. Measuring a panel of tumor markers as was 
proposed for the diagnosis in pleural effusion also does not provide a much higher 
sensitivity. At present, for the confirmation of the diagnosis of malignant pericardial 
effusion, there is a firm recommendation for the assessment of CEA and CYFRA 21-1 (23-
26). Open pericardial biopsy or pericardoscopy with visualisation of the pericardial surface 
and guided biopsies of suspicious areas can identify most of the remaining cases (5). A 
search for the primary tumour must be undertaken because metastases to the pericardium 
are much more common than the primary tumour and furthermore,  primary tumors of the 
heart are far less common than metastatic tumours to the heart. Primary tumours of the 
pericardium are usually sarcomas or mesotheliomas (27,28). The metastatic cancer is most 
often carcinoma of the lung (40%), breast (22%), leukemia and lymphoma (15%), sarcomas 
(3.5%) and melanoma (2.7%) (10).  
The reason for the heart and the pericardium not being affected by primary cancer, and 
cardiac tissue mostly being invaded by the metastatic process can probably be explained 
with the concept of immune privilege which was first proposed in the 1940s by the Nobel 
laureate, P.B. Medawar and colleagues. At present, the eye, brain and reproductive organs 
are endowed with immune privilege where inflammation is self-regulated so as to preserve 
organ functions (29,30). There are also a lot of reports which might indicate self-regulated 
inflammation of the heart and pericardium as well. The reaction of cardiac tissue to acute 
injury involves interacting cascades of cellular and molecular responses that encompass 
inflammation, hormonal signalling, extracellular matrix remodelling, and compensatory 
adaptation of cardiomyocytes. There is a significant importance of acute inflammation 
occurring during acute myocardial infarction where the infarct scar is a dynamic tissue: 
cellular, vascularised, metabolically active and contractile. Although the induction of pro-
inflammatory mediators is important for the clearance of the wound from dead 
cardiomyocytes and matrix debris, the activation of inflammatory pathways is transient and 
followed by the repression of inflammatory gene synthesis and the resolution of the 
leukocytic infiltrate (31). There is also evidence of heart specific cardiomyocytes apoptosis 
and changes in interstitial tissue of the heart in the progression of heart failure, as in 
hypertension, myocarditis and after myocardial infarction. Ongoing inflammation is of great 
importance in chronic heart failure. The marker of inflammation, the C-reactive protein 
(CRP), is elevated in chronic heart failure and is produced by the liver in response to 
cytokines such as IL-1, IL-6, and TNF-alpha. Inflammatory cytokines and chemokines plays 
an active role in cardiac deterioration in chronic heart failure through the induction of 
endothelial dysfunction and apoptosis of cardiomyocytes (32,33). Therefore, a chronic 
inflammatory response in heart and vessels also produces different end stage complications 
compared to other tissue and due to their close interaction with angiogenesis, apoptosis and 
www.intechopen.com
 
Inflammatory Diseases – Immunopathology, Clinical and Pharmacological Bases 
 
204 
cell proliferation. Cardiac tissue specific immune response may also influence 
carcinogenesis (34). Plausible immune privilege of the heart and pericardium can also be 
due to the complex structure of the lymphatic system in the heart, which is a three-tiered 
structure: the subepicardial, the myocardial and the subendocardial nets and drain from the 
heart to the mediastinum. Considering that lymphatics represent the major route to cardiac 
metastases, a blockade of the common lymphatic node by neoplastic cells coming from the 
metastasised mediastinum lymph nodes is a key event leading to the formation of 
metastases (35). Immune privilege might explain the relatively low incidence of secondary 
tumors in the heart compared with other organs.  
4. Treatment 
The ideal treatment for pericardial effusion ensures the complete removal of fluid, relives 
tamponade if present and therefore relives symptoms. Other goals in the treatment are to 
prevent recurrent effusion and treat the local neoplastic disease with the aim of prolonging 
survival.  
Pericardiocentesis using the Seldinger technique is successful in removing fluid and 
alleviating symptoms in 97% of patients, with 3% of major complications (6,36). There is 
only a sporadic report on the rate of recurrence of pericardial effusion which was reported 
to be 40%, without additional treatment (36,37). The number of patients reported in 
literature not receiving any additional therapy is too small to make a firm conclusion of the 
spontaneous re-accumulation rate of malignant effusion after pericardiocentesis (38-41). 
Tsang et al. reported of reducing the rate of recurrence by extending the drainage for several 
days (6,37). The indwelling pericardial catheter was left in place in the study of Gatenbey et 
al. for 4.8 days (42), but in the majority of studies it was used in conjunction with systemic 
therapy or sclerosing agents.   
The rationale for sclerosing therapy is to prevent the recurrence of effusion by creating 
adhesions of the visceral and parietal pericardium. Antibiotic agents doxycycline and 
previously tetracycline were first used as pure sclerosing agents for this purpose with short-
term efficacy in preventing early recurrences (43,44-46). It should be noted, however, that 
the effusion control of tetracyclines is only due to sclerosing activity and not to specific 
antineoplastic action. Tetracyclines have many adverse effects and a potential for the 
development of the constrictive pericarditis secondary to fibrosis in long-term survivors 
(table 1). The OK-432, an immunomodulator available in Japan has been used in small group 
of patients with neoplastic pericarditis. Despite that, the OK-432 has the ability to stimulate 
cell-mediated immunity and besides the direct cytotoxic effect against malignant cells it has 
no significant advantages over other agents. The OK-432 also has common side effects (47). 
Bleomycin and thiotepa are anticancer agents with sclerosing properties and are used for 
local therapy with good results and few side effects (45,48-52).  
The rationale for intrapericardial instillation of the antineoplastic drug is to provide a high 
and long-lasting concentration of the intrapericardial drug. Various chemotherapeutic 
agents have been used for local chemotherapy with the purpose to prevent recurrent 
effusion or prolong the effusion-free period and prolong survival. The use of 
intrapericardial cis-platinum was first reported in 1985 and after that drug was often used 
(41,53-57). Nitrogen mustard, mitomycin C, mitoxantrone and 5-fluorouracil have also been 
used intrapericardially (58-62). The reported experiences with sclerosing agents and 
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chemotherapeutic agents are summarized in table 1. Lestuzzi et al. have suggested a 
“tumour specific” treatment algorithm for neoplastic pericardial effusion in which he 
preferred cisplatin in pericardial lung carcinoma metastases and bleomycin in pericardial 
breast carcinoma metastases. Authors reported a low complication rate and significant 
effectiveness of local chemotherapy. On the basis of personal experience and the review of 
literature, they conclude that sclerosing therapy should not be considered as the first choice 
 
 
Itrapericardial 
treatment 
(references) 
Chemical natures and 
action 
Treatment 
success 
(%) 
Current
use 
Side effects and 
complications 
Tetracycline 
or Doxycyline 
(43-46)  
Antibiotics 
sclerosis 
73-75  Severe pain (15-70%) 
Atrial arrhythmias (9-10%) 
Fever (7.5-50%) 
Infection (0.5%) 
Constriction (2%) 
OK-432  
(47) 
Immunomodulator 70  Fever (60%) 
Pain (50%) 
Bleomycin  
(45,48,49) 
Antineoplastic agent, 
Antibiotic 
Inhibits synthesis of 
DNA and sclerosis  
71-100  Constriction (2.4%) 
Fever (18%) 
Atrial fibrillation (9%) 
Thiotepa 
(50-52) 
Antineoplastic agent, 
Alkylating agent  
79-91  Thrombocytopenia (0.9%) 
Leucopoenia (0.9%) 
Mitomycin C 
(58) 
Antineoplastic agent, 
Antibiotic 
Act like an alkylating 
agent 
70  Constriction after several 
months (5%) 
Mitoxantrone  
(59) 
Antineoplastic agent, 
Anthracenedione 
Inhibits DNA and 
RNA synthesis 
60  None 
Cisplatin  
(41,42,53-57)  
Antineoplastic agent, 
Alkylating agent 
Inhibits DNA 
synthesis 
50-100  Nausea (6.7%) 
Atrial arrhythmias (4.4%) 
Constriction (1.1%) 
Myocardial ischemia (1%) 
Nitrogen 
mustard 
(60,61) 
Antineoplastic agent, 
Alkylating agent 
Inhibits DNA and 
RNA synthesis 
100  Pain (% no report) 
Nausea (% no report) 
Vomiting (% no report) 
Leucopenia (% no report) 
Fever (% no report) 
5-Fluorouracil 
(62) 
Antineoplastic agent, 
Pyrimidine analogue- 
Antimetabolite 
Interferes with DNA 
and RNA synthesis 
100  Nausea (% no report) 
Leucopenia (% no report) 
Premature beats (% no 
report) 
Table 1. . 
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therapy for malignant pericardial effusion because the goal of treatment is not simply to 
mechanically prevent the accumulation of pericardial fluid, but trying to cure pericardial 
metastases (63). 
Systemic chemotherapy and radiation therapy are successfully used in breast cancer and 
leukemia and lymphoma after the initial pericardiocentesis to prevent the recurrence of 
effusion and to treat primary cancer (37-39). In cases of recurrent effusion and persistent 
symptoms various surgical drainage procedures are available. Total pericardiectomy is 
seldom performed today for pericardial effusions associated with malignancy because the 
operative risks are too high. Recent literature favours the creation of a pericardial window 
either by thoracotomy, by a subxiphoid route, or by thoracoscopy (40).  
The epidemiology, therapy, and prognosis of neoplastic pericarditis have changed over 
time. The comparison of many observational studies is misleading, since in the largest 
studies, different tumours and/or different treatments were analyzed together. The most 
important bias in the articles reporting the efficacy of various local treatments is the 
concomitant use of systemic chemotherapy. 
5. Conclusion 
Clinical suspicion of pericardial involvement is crucial for the identification of a patient with 
neoplastic pericarditis because of non-specific symptoms and signs and because chest x-ray, 
ECG and even echocardiographic findings are not 100% sensitive or specific either. 
Pericardiocentesis provides the diagnosis and offers this group of patients immediate relief, 
but trials with various chemotherapeutic agents and radiotherapy, in addition to the new 
surgical procedure will hopefully change the survival rate for this group of oncologic 
patients. 
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